secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2026-08-11T12:40:21+00:00
Accession:  0001493152-26-036996
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech CEO op-ed touts Ampligen as biodefense antiviral; cites 100% Ebola survival in mouse model
--------------------------------------------------------------------------------

- CEO Thomas K. Equels published op-ed in Breaking Defense on Aug 11, 2026 promoting Ampligen (rintatolimod) as broad-spectrum antiviral.
- USAMRIID preclinical study cited: 100% survival in rintatolimod-treated Ebola mouse cohort vs 100% mortality in controls (Antiviral Research).
- Company seeking government support for further Ebola/Bundibugyo and coronavirus mechanism studies; cites Utah State SARS research.
- Disclosure: Ampligen not FDA-approved for Ebola, Bundibugyo, coronaviruses or any biodefense indication.
- Op-ed references ~1,200 COVID infections aboard USS Theodore Roosevelt to argue for biodefense preparedness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315226036996/0001493152-26-036996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315226036996/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-036996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer